Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03672175 Not yet recruiting - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

Start date: September 2018
Phase: Phase 3
Study type: Interventional

This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult subjects with major depressive disorder

NCT ID: NCT03670823 Not yet recruiting - Major Depression Clinical Trials

Prediction of SSRI Treatment in Major Depression.

Start date: October 1, 2018
Study type: Observational

This project will combine the data collected from EEG, Eye tracking, structural and functional MRI scans and neuropsychological performance from patients with major depression receiving SSRI treatment. The purpose of this research is to predict the success of the SSRI treatment and to categorize patients into sub-groups according to similar patterns of brain activation to personalize treatment.

NCT ID: NCT03668457 Not yet recruiting - Depressive Disorder Clinical Trials

A Multi-component Intervention to Improve Medication Adherence in People With Depressive Disorders

Start date: September 2018
Phase: N/A
Study type: Interventional

Objective: The study of medication adherence in depression (MAPDep study) aims to evaluate the effectiveness and cost-effectiveness of a multi-component strategy to enhance patient-centered care to improve adherence toward medications in patients with depression, formed by an educational intervention to psychiatrists and/or a collaborative care intervention group to patients and relatives plus a reminder system through the use of a mobile APP. Methods: The objective will be assessed under an open multicenter, clinical controlled trial with random allocation by clusters to one of three interventions or to usual care (control arm). In group 1 only patients and family members receive intervention, in group 2 only psychiatrists receive intervention, and group 3 is a combined intervention for patients and psychiatrists. The main measure will be the change in medication adherence rate. Secondary endpoints are depression, emotional distress, health-related quality of life, physical functioning, patients' knowledge about their medications, provider beliefs regarding patient-centeredness, and healthcare resource utilization.

NCT ID: NCT03668379 Not yet recruiting - Depression Clinical Trials

An Adaptive Intervention for Depression Among Latinos Living With HIV.

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This study will use a pilot sequential multiple assignment randomized trial (SMART) design to build an adaptive treatment strategy (ATS) for depression and engagement in HIV among Latinos living with HIV. The ATS is the sequencing of treatments, which are a behavioral activation therapy (BAT), a cognitive-behavioral therapy (CBT), and mobile health (mHealth) tool. The outcomes are to assess the feasibility of the SMART and ATS in the HIV care site and acceptability of the SMART and ATS to patients and clinic staff.

NCT ID: NCT03668223 Not yet recruiting - Depression Clinical Trials

The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer

Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer

NCT ID: NCT03667872 Not yet recruiting - Clinical trials for Treatment Resistant Depressive Disorder

Efficacy and Safety of DBS in Patients With Treatment-Resistant Depression

Start date: September 18, 2018
Phase: N/A
Study type: Interventional

The habenula (Hb) is an ancient structure, located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions. An increasing number of studies indicated that the lateral habeluna (LHb) is overactivity during depressive behaviors in rats, where it could drive the changes in midbrain monoamine neurotransmitter linked to depression. However, the efficiency and mechanism of deep brain stimulation (DBS) of the LHb and/or its major afferent bundle (i.e., stria medullaris thalami) could treat treatment-resistant major depression (TRD) is still unclear. This research will investigate the effectiveness and mechanism of bilateral MRI Compatible and Long-term LFP Recordable DBS to habenula and/or its major afferent bundle for treatment TRD patients.

NCT ID: NCT03666494 Not yet recruiting - Depression Clinical Trials

Ketamine Co-induction for Patients With Major Depressive Disorder

Start date: December 2018
Phase: Phase 4
Study type: Interventional

Ketamine hydrochloride, an anesthetic medication, has been demonstrated to acutely and rapidly improve depressive symptoms but not yet been adequately studied for this effect when used as part of a general anesthetic for surgery. This proposed single-centre, double-blinded, randomized clinical trial of adult patients with depression presenting for gynecologic surgery would compare severity of depressive symptoms between patients receiving and not receiving ketamine as part of their general anesthetic.

NCT ID: NCT03665831 Not yet recruiting - Clinical trials for Major Depressive Disorder

Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults

Start date: October 2018
Phase: N/A
Study type: Interventional

In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate AD and comorbid MDD who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left DLPFC. The investigators propose that active stimulation with the H1 coil will result in higher remission rates than placebo stimulation but will have a similar tolerability and safety profile.

NCT ID: NCT03662581 Not yet recruiting - Depression Clinical Trials

Evaluating a Primary-Care Group-based Mindfulness Program

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

The study evaluates the effectiveness of a group-based mindfulness program conducted in a primary care setting. This study also aims to identify any scale-up and implementation considerations for the program.

NCT ID: NCT03661580 Not yet recruiting - Depression Clinical Trials

BA Trial for Co-Occurring Depression and Substance Use

Start date: September 12, 2018
Phase: N/A
Study type: Interventional

A large proportion of people seeking treatment for drug and alcohol issues also have clinically significant depression symptoms. This combination of problems tends to have a negative impact on treatment and leads to poor health and disability, yet relatively few studies have focused on the development of interventions for treating this comorbidity. There is emerging evidence to suggest that Behavioural Activation (BA) may be a viable and cost-effective treatment for comorbid depression and substance use problems, however more research is needed in order to establish its effectiveness in routine practice. The aim of this study is therefore to investigate the efficacy of a brief (6-session), manualised BA intervention among service users with depression who are accessing Community Drugs and Alcohol treatment. We are planning to recruit up to 128 service users who are actively using substances to be randomly assigned to either the 6-week BA intervention or Treatment as Usual in Community Drugs and Alcohol services. These participants will be recruited from either a Community Drugs and Alcohol service or a Community Mental Health service. Our research will assess whether the BA intervention is more effective than usual care in (1) reducing depression symptoms, (2) reducing substance use, and (3) improving treatment engagement (i.e. session attendance). We expect that our results will establish the efficacy of integrating BA for depression into routine Community Drugs and Alcohol Treatment.